An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
| Title | An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab plus Ipilimumab, or Nivolumab plus platinum doublet chemotherapy versus platinum doublet chemotherapy in Subjects with Chemotherapy-Naive Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) |
|---|---|
| Description | The study will submit its CSR data to Health Authority of Japan. |
| Organism | Homo sapiens |
| Data Type | Biomarker Data |
| Data Accessibility | Controlled-access |
| BioProject | PRJCA013230 |
| Release Date | 2022-12-31 |
| Submitter | Xiaoxiao Wang (mandy.wang@bms.com) |
| Organization | Bristol-Myers Squibb (China) Investment Co., Ltd. |
| Submission Date | 2022-11-15 |
HTTP download speed may be slow. It is highly recommended that you download the dataset using a dedicated FTP tool (such as FileZilla Client).
| File ID | File Title | Number/Samples | File Type | File Size | File Suffix | Download Times | Download |
|---|---|---|---|---|---|---|---|
| OMIX002353-01 | CA209-227 part 2 Backup Dataset | 113 | Biomarker Data | 18.6 MB | zip | 0 | Controlled |